An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: the OPTIMA-2 randomized controlled trial.

[1]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[2]  Deepak L. Bhatt,et al.  Meta‐analysis of optimal timing of coronary intervention in non‐ST‐elevation acute coronary syndrome , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  C. McCoy,et al.  Understanding the Intention-to-treat Principle in Randomized Controlled Trials , 2017, The western journal of emergency medicine.

[4]  E. Vicaut,et al.  Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials , 2017, The Lancet.

[5]  M. Ašanin,et al.  Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients: The RIDDLE-NSTEMI Study. , 2016, JACC. Cardiovascular interventions.

[6]  J. Tijssen,et al.  Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. The ‘wait a day’ approach might be safer , 2016, Netherlands Heart Journal.

[7]  H. Benamer,et al.  Early invasive strategy in high-risk acute coronary syndrome without ST-segment elevation. The Sisca randomized trial. , 2015, International journal of cardiology.

[8]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[9]  P. Dobesh,et al.  Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety , 2014, Pharmacotherapy.

[10]  A. W. van ‘t Hof,et al.  Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  G. Schuler,et al.  Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). , 2012, European heart journal.

[12]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[13]  R. Teng,et al.  Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. , 2010, British journal of clinical pharmacology.

[14]  S. Yusuf,et al.  Early versus delayed invasive intervention in acute coronary syndromes. , 2009, The New England journal of medicine.

[15]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[16]  E. Vicaut,et al.  Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. , 2009, JAMA.

[17]  D. Roberts,et al.  Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes , 2009 .

[18]  Stanley Chia,et al.  Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. , 2008, JACC. Cardiovascular interventions.

[19]  A. Kastrati,et al.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[20]  S. Yusuf,et al.  Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes , 2003, Circulation.

[21]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.